EN DE

Aoyuan Healthy Life Group (3662) Fair Value & Analysis

Real Estate · HK · Market cap HK$265M

AH Aoyuan Healthy Life Group 3662 · HK
PriceHK$0.3400
Fair ValueHK$0.2633
Upside-22.6%
Quality54/100
Watch Aoyuan Healthy Life Group for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 4.2% net margin
generates free cash flow
Mixed vs. peers (7/12)
Narrow moat 29/100
Evidence: High Range HK$0.2097 – HK$0.3284 Share as image

Fair value as of: Aug 13, 2026

From 16 valuation models · updated 3 days ago

Fair value updated Aug 13, 2026, revised from HK$0.2630 to HK$0.2633 (+0.1%) since Aug 6, 2026. Share price −11.7% over the past month.

A solid business, but screening 23% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (HK$0.3284). The favourable scenario is already priced in.
  • Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
  • As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$6.62 HK$0.2700 Fair Value HK$0.2633 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.2700 – HK$6.62 · fair‑value band HK$0.2097 – HK$0.3284 · the HK$0.3400 price screens above the HK$0.2633 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aoyuan Healthy Life Group (3662) currently trades at HK$0.3400, while our model-based Fair Value estimate is HK$0.2633, implying the stock looks roughly 22.6% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Real Estate sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Aoyuan Healthy Life Group generated revenue of HK$1.2B at a net margin of 4.2%. Revenue declined 7.1% year over year. It earns a return on equity of 3.9%. The balance sheet holds a net cash position of HK$942M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.2097 (bear case) to HK$0.3284 (bull case); at HK$0.3400, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 44% below its 52-week high and 28% above its 52-week low, currently below its 200-day average. For context, the median of 10 Real Estate peers we cover trades at 15% fair-value upside, at -23%, 3662 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income HK$1.12 HK$1.08 HK$0.8600 76
Growth DCF HK$1.74 HK$1.84 HK$1.96 72
Gordon GGM HK$0.1800 HK$0.3000 HK$0.3900 70
All 16 models by family
DCF Models
FCF DCF HK$1.74 HK$1.86 HK$2.00 38
5Y Revenue Exit HK$2.19 HK$2.74 HK$3.43 39
5Y EBITDA Exit HK$2.57 HK$3.43 HK$4.42 41
10Y Revenue Exit HK$1.95 HK$2.35 HK$2.87 36
10Y EBITDA Exit HK$2.18 HK$2.75 HK$3.50 37
Dividend Discount
Gordon GGM HK$0.1800 HK$0.3000 HK$0.3900 70
DDM Multi-Stage HK$0.1800 HK$0.2500 HK$0.3200 61
Multiples
P/S Multiple HK$0.9100 HK$1.21 HK$1.51 58
P/B Multiple HK$0.9100 HK$1.21 HK$1.51 55
EV/EBIT HK$3.65 HK$4.41 HK$5.16 53
EV/EBITDA HK$3.51 HK$4.22 HK$4.93 54
EV/Revenue HK$2.64 HK$3.17 HK$3.71 43
Asset-Based
NCAV (Graham) HK$0.8300 HK$1.11 HK$1.66 50
Growth DCF
Growth DCF HK$1.74 HK$1.84 HK$1.96 72
Rev-Margin DCF HK$2.19 HK$2.73 HK$3.32 67
Economic Profit
Residual Income HK$1.12 HK$1.08 HK$0.8600 76

Widest divergence: Multiples (HK$3.17) versus Dividend Discount (HK$0.2500). Highest evidence: Residual Income (76).

Notify me when 3662 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$1.2B
Revenue growth (YoY) -7.1%
Net margin 4.2%
Return on equity 3.9%
Free cash flow HK$31.6M FY2025
P/E ratio 4.6 as of Jul 2, 2026
More key figures
Operating margin 7.7%
EPS (TTM) HK$0.0300
EPS growth (YoY) +82.4%
Net cash HK$942M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 57 · Market factors (momentum, volatility) 33

Profitability 29
Margins and returns on capital today
Quality Growth 26
Are margins and returns improving?
Cashflow 36
Earnings quality: real cash, not paper profit
Fin. Strength 95
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 59
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Starjoy Wellness and Travel Company Limited, through its subsidiaries, provides property management and commercial operational services in the People's Republic of China. The company operates through Property Management Services and Commercial Operational Services segments.

Full company description

Starjoy Wellness and Travel Company Limited, through its subsidiaries, provides property management and commercial operational services in the People's Republic of China. The company operates through Property Management Services and Commercial Operational Services segments. It offers property management services for residential communities, commercial complexes, office buildings, villas, and tourist towns; and sales assistance services, community value-added services, and heating services for both residential and non-residential units to property developers, property owners, and residents. The company also provides commercial operation and management services and market positioning, and business tenant sourcing services to commercial property developers and commercial property lessees. In addition, it engages in the operation of the mobile application; provision of cleaning and gardening, design management and consulting, decoration and furniture, engineering consulting, and health management services. The company was formerly known as Aoyuan Healthy Life Group Company Limited and changed its name to Starjoy Wellness and Travel Company Limited in January 2024. The company was founded in 2000 and is based in Guangzhou, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Aoyuan Healthy Life Group reported revenue of HK$1.2B in FY2025 versus HK$1.9B in FY2021, a compound −11.0%/yr. Reported net income was HK$51.6M in FY2025.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$1.2B
Latest YoY
−10.0%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−9.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−2.8%
Avg. growth/yr (10Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+21.1%
Revenue −11.0%/yr
FY21 HK$1.9B
FY22 HK$1.6B
FY23 HK$1.6B
FY24 HK$1.4B
FY25 HK$1.2B
Net income
FY21 −HK$191M
FY22 HK$160M
FY23 HK$157M
FY24 HK$96.2M
FY25 HK$51.6M
Character of growth · EPS growth decomposed (2015-2025) +13.3 % p.a.
Revenue per share +23.4 pp

of which total revenue +23.9 pp · buybacks/dilution −0.5 pp

EBIT margin −8.7 pp
Tax rate +1.0 pp
Residual (interest, one-offs) −2.4 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

3662 screens 23% overvalued. Compare with Plaza S.A →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Aoyuan Healthy Life Group Fair Value". https://www.fairvalue-calculator.com/stock/3662

Peer Group

Real Estate Services · 529 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 56 · Above median
Fair Value upside −24% · Below median
Return on equity (TTM) 4% · Below median
Return on assets 3% · Above median
Net margin (TTM) 4% · Below median
Operating margin (TTM) 8% · Below median
Revenue growth -7% · Below median
Dividend yield (TTM) 7.1% · Top 25%

Valuation Multiples vs Real Estate Services median · lower = cheaper

P/E (TTM) 4.6× · Cheaper than 75% of peers
P/B 0.22× · Cheaper than 75% of peers
P/S (TTM) 0.22× · Cheaper than 75% of peers
P/FCF 1.1× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 2 · sector 34
FUTURE 0 · sector 10
PAST 16 · sector 16
HEALTH 0 · sector 85
DIVIDEND 100 · sector 59

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Real Estate Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Plaza S.A MALLPLAZA 3,989 CLP 4,571 CLP +15%
PT Solusi Tunas Pratama Tbk SUPR 43,850 IDR 15,049 IDR -66%
Cencosud Shopping S.A CENCOMALLS 2,412 CLP 2,976 CLP +23%
PT Sarana Menara Nusantara Tbk. owns and TOWR 392.00 IDR 1,012 IDR +158%
PT Metropolitan Kentjana Tbk MKPI 22,000 IDR 19,160 IDR -13%
PT Bangun Kosambi Sukses Tbk, CBDK 3,610 IDR 3,464 IDR -4%
IRSA Inversiones y Representaciones Sociedad Anónima, IRSA 2,495 ARS 2,990 ARS +20%
PT Plaza Indonesia Realty Tbk PLIN 2,510 IDR 2,698 IDR +7%
PT MNC Tourism Indonesia Tbk, KPIG 74.00 IDR 122.12 IDR +65%
PT Indonesian Paradise Property Tbk INPP 770.00 IDR 291.52 IDR -62%

Compare Aoyuan Healthy Life Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Real Estate stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Aoyuan Healthy Life Group (3662) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.2633 versus a price of HK$0.3400, about −23% (overvalued).
What is the fair value of 3662?
Our model-based fair value for Aoyuan Healthy Life Group is HK$0.2633 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$0.3400.
What is the quality score of 3662?
Aoyuan Healthy Life Group has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Aoyuan Healthy Life Group (3662)?
Aoyuan Healthy Life Group reported trailing-twelve-month revenue of about HK$1.2B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 3662?
The net profit margin of Aoyuan Healthy Life Group is about 4.2%, meaning it keeps roughly 4.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Aoyuan Healthy Life Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.